Last reviewed · How we verify
SH006
At a glance
| Generic name | SH006 |
|---|---|
| Sponsor | Nanjing Sanhome Pharmaceutical, Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma (PHASE2, PHASE3)
- A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SH006 CI brief — competitive landscape report
- SH006 updates RSS · CI watch RSS
- Nanjing Sanhome Pharmaceutical, Co., Ltd. portfolio CI